Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME) - The Manila Times
- news.google.com language
- 2025-06-09 23:35 event
- 10 hours ago schedule